CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
We have now added a new section called the "Assay History List" to the "At A Gla...